[
  {
    "ts": null,
    "headline": "This Is Graco’s Dividend Score After Paying Investors",
    "summary": "Graco just paid investors $0.295 per share on February 4, 2026, marking the company’s 27th consecutive year of quarterly dividend payments. This industrial equipment manufacturer has quietly built one of the more consistent dividend growth records in the specialty machinery sector, with a 5-year compound annual growth rate of approximately 9.4%. But consistency alone doesn’t ... This Is Graco’s Dividend Score After Paying Investors",
    "url": "https://finnhub.io/api/news?id=f5eec16e022d376fe0246cae7b57d34d0cfc9beb584bef3a566290f3c5229468",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770917856,
      "headline": "This Is Graco’s Dividend Score After Paying Investors",
      "id": 139073098,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Graco just paid investors $0.295 per share on February 4, 2026, marking the company’s 27th consecutive year of quarterly dividend payments. This industrial equipment manufacturer has quietly built one of the more consistent dividend growth records in the specialty machinery sector, with a 5-year compound annual growth rate of approximately 9.4%. But consistency alone doesn’t ... This Is Graco’s Dividend Score After Paying Investors",
      "url": "https://finnhub.io/api/news?id=f5eec16e022d376fe0246cae7b57d34d0cfc9beb584bef3a566290f3c5229468"
    }
  },
  {
    "ts": null,
    "headline": "IRWD Rises 307% in 6 Months: Is This an Indication to Buy the Stock?",
    "summary": "Ironwood surges 307% in six months on rising Linzess demand and an upbeat 2026 revenue outlook. The company is also making good pipeline progress.",
    "url": "https://finnhub.io/api/news?id=6dcf06a6fd277f211e14a3b447f67bb76c9dadaa5284d731c84f75ee33cbfa2a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770910500,
      "headline": "IRWD Rises 307% in 6 Months: Is This an Indication to Buy the Stock?",
      "id": 139066837,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Ironwood surges 307% in six months on rising Linzess demand and an upbeat 2026 revenue outlook. The company is also making good pipeline progress.",
      "url": "https://finnhub.io/api/news?id=6dcf06a6fd277f211e14a3b447f67bb76c9dadaa5284d731c84f75ee33cbfa2a"
    }
  },
  {
    "ts": null,
    "headline": "Is It Too Late To Consider AbbVie (ABBV) After Its Strong Multi Year Run?",
    "summary": "If you are wondering whether AbbVie shares still offer value after a strong multi year run, this article walks through what the current price might be implying. The stock last closed at US$220.89, with returns of 1.7% over 7 days, 0.4% over 30 days, a 3.7% decline year to date, 18.3% over 1 year, 63.0% over 3 years and 151.6% over 5 years. Recent headlines around AbbVie have focused on its large cap pharmaceutical profile and on how investors are weighing its long term product portfolio...",
    "url": "https://finnhub.io/api/news?id=7ead1966509d5c3f56ddfca93b0ebbafa5475b9005e54a821222b7b42724a07c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770898488,
      "headline": "Is It Too Late To Consider AbbVie (ABBV) After Its Strong Multi Year Run?",
      "id": 139055899,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "If you are wondering whether AbbVie shares still offer value after a strong multi year run, this article walks through what the current price might be implying. The stock last closed at US$220.89, with returns of 1.7% over 7 days, 0.4% over 30 days, a 3.7% decline year to date, 18.3% over 1 year, 63.0% over 3 years and 151.6% over 5 years. Recent headlines around AbbVie have focused on its large cap pharmaceutical profile and on how investors are weighing its long term product portfolio...",
      "url": "https://finnhub.io/api/news?id=7ead1966509d5c3f56ddfca93b0ebbafa5475b9005e54a821222b7b42724a07c"
    }
  },
  {
    "ts": null,
    "headline": "1 Reason I'm Never Selling AbbVie Stock",
    "summary": "This Dividend King has staying power.",
    "url": "https://finnhub.io/api/news?id=6497a695c1ae2124110ec33317de77345797782be85b3407a436f0605b0f664a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770890640,
      "headline": "1 Reason I'm Never Selling AbbVie Stock",
      "id": 139054558,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "This Dividend King has staying power.",
      "url": "https://finnhub.io/api/news?id=6497a695c1ae2124110ec33317de77345797782be85b3407a436f0605b0f664a"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. (ABBV) Achieves Record Net Sales  on Diversified Growth Platform",
    "summary": "AbbVie Inc. (NYSE:ABBV) is one of the best long-term stocks to invest in for retirement. On February 6, Cantor Fitzgerald reiterated its Overweight rating on AbbVie Inc. (NYSE:ABBV) with a $250 price target. The positive outlook follows solid fourth-quarter 2025 results, as Skyrizi sales topped estimates and the company provided guidance above consensus. On February […]",
    "url": "https://finnhub.io/api/news?id=e62259515012de50ca693e1e1b6052a21bed9db549d0df7accbec95f6d077e74",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770889358,
      "headline": "AbbVie Inc. (ABBV) Achieves Record Net Sales  on Diversified Growth Platform",
      "id": 139053887,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie Inc. (NYSE:ABBV) is one of the best long-term stocks to invest in for retirement. On February 6, Cantor Fitzgerald reiterated its Overweight rating on AbbVie Inc. (NYSE:ABBV) with a $250 price target. The positive outlook follows solid fourth-quarter 2025 results, as Skyrizi sales topped estimates and the company provided guidance above consensus. On February […]",
      "url": "https://finnhub.io/api/news?id=e62259515012de50ca693e1e1b6052a21bed9db549d0df7accbec95f6d077e74"
    }
  },
  {
    "ts": null,
    "headline": "54 Stocks, 9 Megatrends: My Favorite Places To Be While Capital Is 'Forced'",
    "summary": "My top-down strategy targets mission-critical sectors where capital is forced by secular and cyclical tailwinds. Check out the list of actionable stock picks here.",
    "url": "https://finnhub.io/api/news?id=8c93ce1a07c0d054c73c6fc4e2314fc285ad939f487e05d175d79bc55224e462",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770881400,
      "headline": "54 Stocks, 9 Megatrends: My Favorite Places To Be While Capital Is 'Forced'",
      "id": 139054949,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2239256494/image_2239256494.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "My top-down strategy targets mission-critical sectors where capital is forced by secular and cyclical tailwinds. Check out the list of actionable stock picks here.",
      "url": "https://finnhub.io/api/news?id=8c93ce1a07c0d054c73c6fc4e2314fc285ad939f487e05d175d79bc55224e462"
    }
  },
  {
    "ts": null,
    "headline": "Evercore ISI Cuts AbbVie Inc. (ABBV) PT, Says Consensus for 2026 and 2027 Still Looks Beatable",
    "summary": "AbbVie Inc. (NYSE:ABBV) is included among the 13 Best Roth IRA Stocks to Buy Now. On February 5, Evercore ISI analyst Gavin Clark-Gartner trimmed his price recommendation on AbbVie Inc. (NYSE:ABBV) to $228 from $232. The analyst maintained an Outperform rating on the stock. In a note to investors, he said that despite Tremfya continuing […]",
    "url": "https://finnhub.io/api/news?id=4ed4406161ad42bd43321848b1d32aad8456049e444c82af8154e21106e1a9c8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770857368,
      "headline": "Evercore ISI Cuts AbbVie Inc. (ABBV) PT, Says Consensus for 2026 and 2027 Still Looks Beatable",
      "id": 139051607,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie Inc. (NYSE:ABBV) is included among the 13 Best Roth IRA Stocks to Buy Now. On February 5, Evercore ISI analyst Gavin Clark-Gartner trimmed his price recommendation on AbbVie Inc. (NYSE:ABBV) to $228 from $232. The analyst maintained an Outperform rating on the stock. In a note to investors, he said that despite Tremfya continuing […]",
      "url": "https://finnhub.io/api/news?id=4ed4406161ad42bd43321848b1d32aad8456049e444c82af8154e21106e1a9c8"
    }
  }
]